MARKET

MGTX

MGTX

Meiragtx Holdings Plc
NASDAQ
5.09
+0.08
+1.60%
After Hours: 5.09 0 0.00% 16:03 04/19 EDT
OPEN
4.960
PREV CLOSE
5.01
HIGH
5.12
LOW
4.890
VOLUME
185.73K
TURNOVER
0
52 WEEK HIGH
8.35
52 WEEK LOW
3.490
MARKET CAP
326.87M
P/E (TTM)
-3.4216
1D
5D
1M
3M
1Y
5Y
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
MeiraGTx Holdings plc is a vertically integrated, clinical stage gene therapy company. The Company gave an oral presentation at the American Academy of Oral Medicine Annual Conference. The conference will be held from April 16-20, 2024 in Orlando, Florida.
Barchart · 1d ago
Weekly Report: what happened at MGTX last week (0408-0412)?
Weekly Report · 4d ago
MeiraGTx Holdings Breaks Above 200-Day Moving Average - Bullish for MGTX
NASDAQ · 04/09 16:21
Weekly Report: what happened at MGTX last week (0401-0405)?
Weekly Report · 04/08 09:19
Private equity firms among MeiraGTx Holdings plc's (NASDAQ:MGTX) largest stockholders and were hit after last week's 10% price drop
Top 6 shareholders of MeiraGTx Holdings plc own 55% of the company. The company is owned by private equity firms with 28% of its shares. The general public holds a 21% stake in the company, with 19% held by institutions. Meira GTx Holdings has an insider ownership of some of the shares in the firm. The group of shareholders may have more power to influence the company's decisions.
Simply Wall St · 04/03 10:02
Weekly Report: what happened at MGTX last week (0325-0329)?
Weekly Report · 04/01 09:18
Weekly Report: what happened at MGTX last week (0318-0322)?
Weekly Report · 03/25 09:19
Weekly Report: what happened at MGTX last week (0311-0315)?
Weekly Report · 03/18 09:18
More
About MGTX
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.

Webull offers MeiraGTx Holdings PLC stock information, including NASDAQ: MGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MGTX stock methods without spending real money on the virtual paper trading platform.